PR Newswire Clinical TrialsOriginal article
ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows
Data ReadoutpositivesemaglutidePositive
AI Analysis
Summary
The FLOW trial presented at ERA Congress demonstrated that once-weekly semaglutide significantly improved health-related quality of life in adults with type 2 diabetes and chronic kidney disease.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Semaglutide significantly improved health-related quality of life in adults with type 2 diabetes and chronic kidney disease
Importance:6/10
Sentiment:
0.75
semaglutideFLOW trialtype 2 diabeteschronic kidney diseasequality of lifeERA Congress
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on June 3, 2026 10:01 PM